Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Savior siblings and Fanconi anemia, analysis of success rates from the family's perspective

  • Trujillo Quintero, Juan Pablo
  • Surralles, Jordi|||0000-0002-4041-7519
Purpose:The current curative treatment of Fanconi anemia is hematopoietic stem cell transplantation; this treatment has a higher rate of successful outcome when donors are compatible siblings. Therefore some families opt to have a healthy and compatible baby after selecting an embryo using preimplantation genetic diagnosis with human leukocyte antigen (HLA) typing. This study aims to estimate the success rate of this procedure from the family's perspective.Methods:Genetic and embryology data were collected from genetic reports provided by the families.Results:A total of 524 oocytes (14.1 oocytes/cycle) and 299 embryos were generated (8.0 embryos/cycle) after 38 in vitro fertilization cycles. Sixteen embryos were transferred to the uterus because they were non-Fanconi anemia and HLA matched. One baby was born. A younger couple delivered a healthy and HLA-compatible baby after four cycles. Therefore, the success rate per cycle is less than 5% (two babies from 42 trials).Conclusion:While Fanconi anemia per se does not worsen the probability of success, a critical factor is advanced maternal age; a late diagnosis leads to few transferrable embryos and high rates of aneuploidy. Families should be informed in advance of the many trials that they will probably need to undergo even if a haploidentical younger relative is available as an oocyte donor.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Fanconi anemia, a model disease for studies on human genetics and advanced therapeutics

  • Bogliolo, Massimo|||0000-0001-8240-7784
Fanconi anemia (FA) is characterized by bone marrow failure, malformations, and chromosome fragility. We review the recent discovery of FA genes and efforts to develop genetic therapies for FA in the last five years. Because current data exclude FANCM as an FA gene, 15 genes remain bona fide FA genes and three (FANCO, FANCR and FANCS) cause an FA like syndrome. Monoallelic mutations in 6 FA associated genes (FANCD1, FANCJ, FANCM, FANCN, FANCO and FANCS) predispose to breast and ovarian cancer. The products of all these genes are involved in the repair of stalled DNA replication forks by unhooking DNA interstrand cross-links and promoting homologous recombination. The genetic characterization of patients with FA is essential for developing therapies, including hematopoietic stem cell transplantation from a savior sibling donor after embryo selection, gene therapy, or genome editing using genetic recombination or engineered nucleases. Newly acquired knowledge about FA promises to provide therapeutic strategies in the near future.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Detectable clonal mosaicism in blood as biomarker of cancer risk in Fanconi anemia

  • Reina-Castillón, Judith
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • López Sánchez, Marcos|||0000-0002-1517-5968
  • Surralles, Jordi|||0000-0002-4041-7519
Detectable clonal mosaicism for large chromosomal events has been associated with aging and an increased risk of hematological and some solid cancers. We hypothesized that genetic cancer predisposition disorders, such as Fanconi anemia (FA), could manifest a high rate of chromosomal mosaic events (CMEs) in peripheral blood, which could be used as early biomarkers of cancer risk. We studied the prevalence of CMEs by single-nucleotide polymorphism (SNP) array in 130 FA patients' blood DNA and their impact on cancer risk. We detected 51 CMEs (4.4-159 Mb in size) in 16 out of 130 patients (12.3%), of which 9 had multiple CMEs. The most frequent events were gains at 3q (n = 6) and 1q (n = 5), both previously associated with leukemia, as well as rearrangements with breakpoint clustering within the major histocompatibility complex locus (P = 7.3 × 10-9). Compared with 15?743 age-matched population controls, FA patients had a 126 to 140 times higher risk of detectable CMEs in blood (P < 2.2 × 10-16). Prevalent and incident hematologic and solid cancers were more common in CME carriers (odds ratio [OR] = 11.6, 95% confidence interval [CI] = 3.4-39.3, P = 2.8 × 10-5), leading to poorer prognosis. The age-adjusted hazard risk (HR) of having cancer was almost 5 times higher in FA individuals with CMEs than in those without CMEs. Regarding survival, the HR of dying was 4 times higher in FA individuals having CMEs (HR = 4.0, 95% CI = 2.0-7.9, P = 5.7 × 10-5). Therefore, our data suggest that molecular karyotyping with SNP arrays in easy-to-obtain blood samples could be used for better monitoring of bone marrow clonal events, cancer risk, and overall survival of FA patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Individuals with FANCM biallelic mutations do no develop Fanconi anemia, but show risk for breast cancer, chemotherapy sensitivity toxicity and may display chromosome fragility

  • Catucci, Irene
  • Osorio, Ana|||0000-0001-8124-3984
  • Arver, Brita
  • Neidhardt, Guido
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Zanardi, Federica
  • Riboni, Mirko
  • Minardi, Simone
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Azzollini, Jacopo
  • Peissel, Bernard|||0000-0001-9233-3571
  • Manoukian, Siranoush
  • Vecchi, De, Giovanna
  • Casola, Stefano
  • Hauke, Jan|||0000-0001-8236-4075
  • Richters, Lisa
  • Rhiem, Kerstin
  • Schmutzler, Rita K.
  • Wallander, Karin
  • Törngren, Therese
  • Borg, Åke
  • Radice, Paolo|||0000-0001-6298-4111
  • Surralles, Jordi|||0000-0002-4041-7519
  • Hahnen, Eric|||0000-0002-1152-8367
  • Ehrencrona, Hans|||0000-0002-5589-3622
  • Kvist, Anders
  • Benitez, Javier|||0000-0002-0923-7202
  • Peterlongo, Paolo|||0000-0001-6951-6855
PurposeMonoallelic germ-line mutations in the BRCA1/FANCS, BRCA2/FANCD1 and PALB2/FANCN genes confer high risk of breast cancer. Biallelic mutations in these genes cause Fanconi anemia (FA), characterized by malformations, bone marrow failure, chromosome fragility, and cancer predisposition (BRCA2/FANCD1 and PALB2/FANCN), or an FA-like disease presenting a phenotype similar to FA but without bone marrow failure (BRCA1/FANCS). FANCM monoallelic mutations have been reported as moderate risk factors for breast cancer, but there are no reports of any clinical phenotype observed in carriers of biallelic mutations.MethodsBreast cancer probands were subjected to mutation analysis by sequencing gene panels or testing DNA damage response genes.ResultsFive cases homozygous for FANCM loss-of-function mutations were identified. They show a heterogeneous phenotype including cancer predisposition, toxicity to chemotherapy, early menopause, and possibly chromosome fragility. Phenotype severity might correlate with mutation position in the gene.ConclusionOur data indicate that biallelic FANCM mutations do not cause classical FA, providing proof that FANCM is not a canonical FA gene. Moreover, our observations support previous findings suggesting that FANCM is a breast cancer-predisposing gene. Mutation testing of FANCM might be considered for individuals with the above-described clinical features.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1

  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Quiles, Francisco
  • Ruiz de Garibay, G.
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Prados-Carvajal, Rosario
  • Fernández-Rodríguez, Juana
  • García, Nadia
  • López, Adrià
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Diez, Orland|||0000-0001-7339-0570
  • Benitez, Javier|||0000-0002-0923-7202
  • Salinas, Monica
  • Teule, Alex|||0000-0003-0028-7200
  • Brunet, Joan|||0000-0003-1945-3512
  • Radice, Paolo|||0000-0001-6298-4111
  • Peterlongo, Paolo|||0000-0001-6951-6855
  • Schindler, Detlev
  • Huertas, Pablo
  • Puente, Xose P.
  • Lázaro, Coxi
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA1 is a tumor suppressor that regulates DNA repair by homologous recombination. Germline mutations in BRCA1 are associated with increased risk of breast and ovarian cancer and BRCA1 deficient tumors are exquisitely sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. Therefore, uncovering additional components of this DNA repair pathway is of extreme importance for further understanding cancer development and therapeutic vulnerabilities. Here, we identify EDC4, a known component of processing-bodies and regulator of mRNA decapping, as a member of the BRCA1-BRIP1-TOPBP1 complex. EDC4 plays a key role in homologous recombination by stimulating end resection at double-strand breaks. EDC4 deficiency leads to genome instability and hypersensitivity to DNA interstrand cross-linking drugs and PARP inhibitors. Lack-of-function mutations in EDC4 were detected in BRCA1/2-mutation-negative breast cancer cases, suggesting a role in breast cancer susceptibility. Collectively, this study recognizes EDC4 with a dual role in decapping and DNA repair whose inactivation phenocopies BRCA1 deficiency.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Functional comparison of XPF missense mutations associated to multiple DNA repair disorders

  • Marín, Maria
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Jia, Nan
  • Ogi, Tomoo
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Surralles, Jordi|||0000-0002-4041-7519
XPF endonuclease is one of the most important DNA repair proteins. Encoded by XPF/ERCC4, XPF provides the enzymatic activity of XPF-ERCC1 heterodimer, an endonuclease that incises at the 5' side of various DNA lesions. XPF is essential for nucleotide excision repair (NER) and interstrand crosslink repair (ICLR). XPF/ERCC4 mutations are associated with several human diseases: Xeroderma Pigmentosum (XP), Segmental Progeria (XFE), Fanconi Anemia (FA), Cockayne Syndrome (CS), and XP/CS combined disease (XPCSCD). Most affected individuals are compound heterozygotes for XPF/ERCC4 mutations complicating the identification of genotype/phenotype correlations. We report a detailed overview of NER and ICLR functional studies in human XPF-KO (knock-out) isogenic cells expressing six disease-specific pathogenic XPF amino acid substitution mutations. Ultraviolet (UV) sensitivity and unscheduled DNA synthesis (UDS) assays provide the most reliable information to discern mutations associated with ICLR impairment from mutations related to NER deficiency, whereas recovery of RNA synthesis (RRS) assays results hint to a possible role of XPF in resolving R-loops. Our functional studies demonstrate that a defined cellular phenotype cannot be easily correlated to each XPF mutation. Substituted positions along XPF sequences are not predictive of cellular phenotype nor reflect a particular disease. Therefore, in addition to mutation type, allelic interactions, protein stability and intracellular distribution of mutant proteins may also contribute to alter DNA repair pathways balance leading to clinically distinct disorders.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The FANCM :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

  • Figlioli, Gisella|||0000-0002-0740-1363
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Catucci, Irene
  • Caleca, Laura|||0000-0002-3381-7493
  • Viz Lasheras, Sandra|||0000-0001-5873-5104
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Kiiski, Johanna I.
  • Muranen, Taru A.|||0000-0002-5895-1808
  • Barnes, Daniel R.|||0000-0002-3781-7570
  • Dennis, Joe|||0000-0003-4591-1214
  • Michailidou, Kyriaki
  • Bolla, Manjeet K.|||0000-0002-4351-9326
  • Leslie, Goska|||0000-0001-5756-6222
  • Aalfs, Cora M.
  • Adank, Muriel A.
  • Adlard, Julian|||0000-0002-1693-0435
  • Agata, Simona
  • Cadoo, Karen
  • Agnarsson, Bjarni A.
  • Ahearn, Thomas
  • Aittomäki, Kristiina
  • Ambrosone, Christine B.
  • Andrews, Lesley
  • Anton-Culver, Hoda
  • Antonenkova, Natalia N.
  • Arndt, Volker|||0000-0001-9320-8684
  • Arnold, Norbert
  • Aronson, Kristan J.
  • Arun, Banu K.
  • Asseryanis, Ella
  • Auber, Bernd|||0000-0003-1880-291X
  • Auvinen, Päivi
  • Azzollini, Jacopo
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Barkardottir, Rosa B.
  • Barrowdale, Daniel|||0000-0003-1661-3939
  • Barwell, Julian
  • Beane-Freeman, Laura
  • Beauparlant, Charles Joly
  • Beckmann, Matthias W.
  • Behrens, Sabine
  • Benitez, Javier|||0000-0002-0923-7202
  • Berger, Raanan
  • Bermisheva, Marina
  • Blanco, Amie M.
  • Blomqvist, Carl
  • Bogdanova, Natalia V.
  • Bojesen, Anders|||0000-0003-4289-8595
  • Bojesen, Stig E.
  • Bonanni, Bernardo|||0000-0003-3589-2128
  • Borg, Åke
  • Brady, Angela F.
  • Brauch, Hiltrud|||0000-0001-7531-2736
  • Brenner, Hermann
  • Brüning, Thomas
  • Burwinkel, Barbara
  • Buys, Saundra|||0000-0003-4120-5697
  • Caldes, Trinidad
  • Caliebe, Almuth
  • Caligo, Maria|||0000-0003-0589-1829
  • Campa, Daniele|||0000-0003-3220-9944
  • Campbell, Ian|||0000-0002-7773-4155
  • Canzian, Federico|||0000-0002-4261-4583
  • Castelao, Jose E.
  • Chang-Claude, Jenny
  • Chanock, Stephen|||0000-0002-2324-3393
  • Claes, Kathleen|||0000-0003-0841-7372
  • Clarke, Christine L.
  • Collavoli, Anita
  • Conner, Thomas A.
  • Cox, David G.
  • Cybulski, Cezary|||0000-0002-2819-3057
  • Czene, Kamila
  • Daly, Mary B.
  • Hoya, Miguel de la|||0000-0002-8113-1410
  • Devilee, Peter|||0000-0002-8023-2009
  • Diez, Orland|||0000-0001-7339-0570
  • Ding, Yuan Chun
  • Dite, Gillian S.
  • Ditsch, Nina
  • Domchek, Susan M.|||0000-0002-5914-7272
  • Dorfling, Cecilia M.
  • dos-Santos-Silva, Isabel
  • Durda, Katarzyna
  • Dwek, Miriam
  • Eccles, Diana M.|||0000-0002-9935-3169
  • Ekici, Arif B.
  • Eliassen, A. Heather
  • Ellberg, Carolina
  • Eriksson, Mikael
  • Evans, Gareth|||0000-0002-8482-5784
  • Fasching, Peter A.
  • Figueroa, Jonine
  • Flyger, Henrik
  • Foulkes, William|||0000-0001-7427-4651
  • Friebel, Tara M.
  • Friedman, Eitan|||0000-0002-6745-1733
  • Gabrielson, Marike
  • Gaddam, Pragna
  • Gago-Dominguez, Manuela
  • Gao, Chi
  • Gapstur, Susan M.
  • Garber, Judy
  • García-Closas, Montserrat
  • García-Sáenz, José A.|||0000-0001-6880-0301
  • Gaudet, Mia M.
  • Gayther, Simon A.|||0000-0001-7937-5443
  • Giles, Graham G.
  • Glendon, Gord
  • Godwin, Andrew K.|||0000-0002-3987-9580
  • Goldberg, Mark S.
  • Goldgar, David E.
  • Guénel, Pascal
  • Gutierrez-Barrera, Angelica M.
  • Haeberle, Lothar
  • Haiman, Christopher A.
  • Håkansson, Niclas
  • Hall, Per
  • Hamann, Ute|||0000-0001-6705-7624
  • Harrington, Patricia A.
  • Hein, Alexander
  • Heyworth, Jane
  • Hillemanns, Peter
  • Hollestelle, Antoinette
  • Hopper, John L.
  • Hosgood, H. Dean
  • Howell, Anthony
  • Hu, Chunling
  • Hulick, Peter J.
  • Hunter, David J.
  • Imyanitov, Evgeny N.
  • Isaacs, Claudine|||0000-0002-9646-1260
  • Jakimovska, Milena|||0000-0002-1506-0669
  • Jakubowska, Anna|||0000-0002-5650-0501
  • James, Paul|||0000-0002-4361-4657
  • Janavicius, Ramunas
  • Janni, Wolfgang
  • John, Esther M.
  • Jones, Michael E.
  • Jung, Audrey
  • Kaaks, Rudolf
  • Karlan, Beth Y.|||0000-0002-9451-2933
  • Khusnutdinova, Elza
  • Kitahara, Cari M.
  • Konstantopoulou, Irene|||0000-0002-0470-0309
  • Koutros, Stella
  • Kraft, Peter
  • Lambrechts, Diether
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Le Marchand, Loic
  • Lester, Jenny
  • Lesueur, Fabienne|||0000-0001-7404-4549
  • Lilyquist, Jenna
  • Loud, Jennifer T.
  • Lu, Karen H.
  • Luben, Robert N.
  • Lubinski, Jan|||0000-0003-2931-3003
  • Mannermaa, Arto
  • Manoochehri, Mehdi
  • Manoukian, Siranoush
  • Margolin, Sara
  • Martens, John W. M.
  • Maurer, Tabea
  • Mavroudis, Dimitrios
  • Mebirouk, Noura
  • Meindl, Alfons
  • Menon, Usha|||0000-0003-3708-1732
  • Miller, Austin|||0000-0001-9739-8462
  • Montagna, Marco
  • Nathanson, Katherine L.|||0000-0002-6740-0901
  • Neuhausen, Susan L.|||0000-0001-5053-0390
  • Newman, William G.
  • Nguyen-Dumont, Tu
  • Nielsen, Finn Cilius
  • Nielsen, Sarah
  • Nikitina-Zake, Liene
  • Offit, Kenneth
  • Olah, Edith
  • Olopade, Olufunmilayo I.|||0000-0002-9936-1599
  • Olshan, Andrew F.
  • Olson, Janet E.
  • Olsson, Håkan
  • Osorio, Ana|||0000-0001-8124-3984
  • Ottini, Laura
  • Peissel, Bernard|||0000-0001-9233-3571
  • Peixoto, Ana
  • Peto, Julian|||0000-0002-1685-8912
  • Plaseska-Karanfilska, Dijana
  • Pocza, Timea
  • Presneau, Nadege
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Punie, Kevin|||0000-0002-1162-7963
  • Rack, Brigitte
  • Rantala, Johanna
  • Rashid, Muhammad U.|||0000-0002-7684-3122
  • Rau-Murthy, Rohini
  • Rennert, Gad|||0000-0002-8512-068X
  • Lejbkowicz, Flavio|||0000-0001-5718-0418
  • Rhenius, Valerie
  • Romero, Atocha|||0000-0002-1634-7397
  • Rookus, Matti A.
  • Ross, Eric A.
  • Rossing, Maria
  • Rudaitis, Vilius
  • Ruebner, Matthias
  • Saloustros, Emmanouil|||0000-0002-0485-0120
  • Sanden, Kristin
  • Santamariña, Marta
  • Scheuner, Maren T.
  • Schmutzler, Rita K.
  • Schneider, Michael
  • Scott, Christopher|||0000-0003-1340-0647
  • Senter, Leigha
  • Shah, Mitul
  • Sharma, Priyanka
  • Shu, Xiao-Ou
  • Simard, Jacques|||0000-0001-6906-3390
  • Singer, Christian F.
  • Sohn, Christof
  • Soucy, Penny
  • Southey, Melissa C.|||0000-0002-6313-9005
  • Spinelli, John J.
  • Steele, Linda
  • Stoppa-Lyonnet, Dominique
  • Tapper, William J.
  • Teixeira, Manuel R.|||0000-0002-4896-5982
  • Terry, Mary Beth
  • Thomassen, Mads
  • Thompson, Jennifer
  • Thull, Darcy L.
  • Tischkowitz, Marc
  • Tollenaar, Rob A. E. M.
  • Torres, Diana
  • Troester, Melissa A.
  • Truong, Thérèse
  • Tung, Nadine
  • Untch, Michael
  • Vachon, Celine M.
  • van Rensburg, Elizabeth J.|||0000-0003-2077-230X
  • van Veen, Elke M.
  • Vega, Ana|||0000-0002-7416-5137
  • Viel, Alessandra|||0000-0003-2804-0840
  • Wappenschmidt, Barbara
  • Weitzel, Jeffrey N.
  • Wendt, Camilla
  • Wieme, Greet|||0000-0003-2718-5300
  • Wolk, Alicja
  • Yang, Xiaohong R.
  • Zheng, Wei|||0000-0003-1226-070X
  • Ziogas, Argyrios|||0000-0003-4529-3727
  • Zorn, Kristin K.
  • Dunning, Alison M.
  • Lush, Michael
  • Wang, Qin
  • McGuffog, Lesley|||0000-0003-1237-0546
  • Parsons, Michael T.
  • Pharoah, Paul D.P.|||0000-0001-8494-732X
  • Fostira, Florentia
  • Toland, Amanda Ewart|||0000-0002-0271-1792
  • Andrulis, Irene L.|||0000-0002-4226-6435
  • Ramus, Susan J.|||0000-0003-0005-7798
  • Swerdlow, Anthony J.
  • Greene, Mark H.|||0000-0003-1852-9239
  • Chung, Wendy
  • Milne, Roger L.|||0000-0001-5764-7268
  • Chenevix-Trench, Georgia
  • Dörk, Thilo|||0000-0002-9458-0282
  • Schmidt, Marjanka K.|||0000-0002-2228-429X
  • Easton, Douglas F.|||0000-0003-2444-3247
  • Radice, Paolo|||0000-0001-6298-4111
  • Hahnen, Eric|||0000-0002-1152-8367
  • Antoniou, Antonis C.
  • Couch, Fergus J.
  • Nevanlinna, Heli|||0000-0002-0916-2976
  • Surralles, Jordi|||0000-0002-4041-7519
  • Peterlongo, Paolo|||0000-0001-6951-6855
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM :p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM :p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM :p.Arg658* and found that also FANCM :p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM :p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM -associated tumors.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Tejero Laguna, Eudald|||0000-0002-7536-4322
  • Rodriguez Santiago, Benjamin|||0000-0003-1167-3852
  • Surralles, Jordi|||0000-0002-4041-7519
Cancer is a complex disease resulting from the accumulation of genetic dysfunctions. Tumor heterogeneity causes the molecular variety that divergently controls responses to chemotherapy, leading to the recurrent problem of cancer reappearance. For many decades, efforts have focused on identifying essential tumoral genes and cancer driver mutations. More recently, prompted by the clinical success of the synthetic lethality (SL)-based therapy of the PARP inhibitors in homologous recombinant deficient tumors, scientists have centered their novel research on SL interactions (SLI). The state of the art to find new genetic interactions are currently large-scale forward genetic CRISPR screens. CRISPR technology has rapidly evolved to be a common tool in the vast majority of laboratories, as tools to implement CRISPR screen protocols are available to all researchers. Taking advantage of SLI, combinatorial therapies have become the ultimate model to treat cancer with lower toxicity, and therefore better efficiency. This review explores the CRISPR screen methodology, integrates the up-to-date published findings on CRISPR screens in the cancer field and proposes future directions to uncover cancer regulation and individual responses to chemotherapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

High content drug screening for Fanconi anemia therapeutics

  • Montanuy, Helena
  • Camps-Fajol, Cristina
  • Carreras-Puigvert, Jordi
  • Häggblad, Maria
  • Lundgren, Bo
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Helleday, Thomas|||0000-0002-7384-092X
  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Surralles, Jordi|||0000-0002-4041-7519
Fanconi anemia is a rare disease clinically characterized by malformations, bone marrow failure and an increased risk of solid tumors and hematologic malignancies. The only therapies available are hematopoietic stem cell transplantation for bone marrow failure or leukemia, and surgical resection for solid tumors. Therefore, there is still an urgent need for new therapeutic options. With this aim, we developed a novel high-content cell-based screening assay to identify drugs with therapeutic potential in FA. A TALEN-mediated FANCA-deficient U2OS cell line was stably transfected with YFP-FANCD2 fusion protein. These cells were unable to form fluorescent foci or to monoubiquitinate endogenous or exogenous FANCD2 upon DNA damage and were more sensitive to mitomycin C when compared to the parental wild type counterpart. FANCA correction by retroviral infection restored the cell line's ability to form FANCD2 foci and ubiquitinate FANCD2. The feasibility of this cell-based system was interrogated in a high content screening of 3802 compounds, including a Prestwick library of 1200 FDA-approved drugs. The potential hits identified were then individually tested for their ability to rescue FANCD2 foci and monoubiquitination, and chromosomal stability in the absence of FANCA. While, unfortunately, none of the compounds tested were able to restore cellular FANCA-deficiency, our study shows the potential capacity to screen large compound libraries in the context of Fanconi anemia therapeutics in an optimized and cost-effective platform.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

CDK5RAP3, a New BRCA2 Partner That Regulates DNA Repair, Is Associated with Breast Cancer Survival

  • Minguillón Pedreño, Jordi|||0000-0003-2124-8294
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Rovirosa Mulet, Llorenç|||0000-0003-2986-9001
  • Bustamante-Madrid, Pilar|||0000-0003-4540-9742
  • Camps-Fajol, Cristina
  • Ruiz de Garibay, Gorka|||0000-0001-9936-8419
  • Shimelis, Hermela
  • Montanuy Escribano, Helena
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Hernández Viedma, Gonzalo|||0000-0002-3048-9607
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Castillo, Pau
  • Soucy, Penny
  • Martrat, Griselda
  • Gómez Moruno, Antonio|||0000-0001-5308-981X
  • Cuadras, Daniel|||0000-0001-8780-1764
  • García, María J.
  • Gayarre, Javier|||0000-0003-0377-6712
  • Lázaro García, Conxi|||0000-0002-7198-5906
  • Benitez, Javier|||0000-0002-0923-7202
  • Couch, Fergus J.
  • Pujana, Miguel Angel|||0000-0003-3222-4044
  • Surralles, Jordi|||0000-0002-4041-7519
BRCA2 is essential for homologous recombination DNA repair. BRCA2 mutations lead to genome instability and increased risk of breast and ovarian cancer. Similarly, mutations in BRCA2-interacting proteins are also known to modulate sensitivity to DNA damage agents and are established cancer risk factors. Here we identify the tumor suppressor CDK5RAP3 as a novel BRCA2 helical domain-interacting protein. CDK5RAP3 depletion induced DNA damage resistance, homologous recombination and single-strand annealing upregulation, and reduced spontaneous and DNA damage-induced genomic instability, suggesting that CDK5RAP3 negatively regulates double-strand break repair in the S-phase. Consistent with this cellular phenotype, analysis of transcriptomic data revealed an association between low CDK5RAP3 tumor expression and poor survival of breast cancer patients. Finally, we identified common genetic variations in the CDK5RAP3 locus as potentially associated with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Our results uncover CDK5RAP3 as a critical player in DNA repair and breast cancer outcomes.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Clinical consequences of BRCA2 hypomorphism

  • Castells Roca, Laia|||0000-0002-4604-9999
  • Gutiérrez-Enríquez, Sara|||0000-0002-1711-6101
  • Bonache, Sandra|||0000-0002-7395-8143
  • Bogliolo, Massimo|||0000-0001-8240-7784
  • Carrasco, Estela|||0000-0003-1964-7675
  • Aza-Carmona, Miriam|||0000-0003-4448-9541
  • Montalban, Gemma|||0000-0002-6958-4759
  • Muñoz-Subirana, N.
  • Pujol Calvet, Maria Roser|||0000-0003-1840-5455
  • Cruz Zambrano, Cristina|||0000-0002-6474-7504
  • Llop Guevara, Alba|||0000-0002-7913-9472
  • Ramírez de Haro, Ma. José|||0000-0003-1417-7731
  • Saura Manich, Cristina|||0000-0001-8296-5065
  • Lasa, Adriana|||0000-0001-9957-9646
  • Serra, Violeta|||0000-0001-6620-1065
  • Diez, Orland|||0000-0001-7339-0570
  • Balmaña Gelpí, Judith|||0000-0002-0762-6415
  • Surralles, Jordi|||0000-0002-4041-7519
The tumor suppressor FANCD1/BRCA2 is crucial for DNA homologous recombination repair (HRR). BRCA2 biallelic pathogenic variants result in a severe form of Fanconi anemia (FA) syndrome, whereas monoallelic pathogenic variants cause mainly hereditary breast and ovarian cancer predisposition. For decades, the co-occurrence in trans with a clearly pathogenic variant led to assume that the other allele was benign. However, here we show a patient with biallelic BRCA2 (c.1813dup and c.7796 A.